SMITHKLINE BEECHAM CONSUMER HEALTHCARE U.S, SALES ADVANCE 18% IN 1993
This article was originally published in The Tan Sheet
SMITHKLINE BEECHAM CONSUMER HEALTHCARE U.S, SALES ADVANCE 18% IN 1993 (at comparable exchange rates), benefiting from continued growth of the Tums antacid line and from the company's OTC partnership with Marion Merrell Dow. Sales for SmithKline Beecham's U.S. consumer healthcare segment, which includes OTC drugs and oral care products, reached $675 mil. (BRITISH POUND)450 for the year, on a (British Pound)1 = $1.50 exchange rate.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC